Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.antiviral.2017.11.017
DC FieldValue
dc.titleAn evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease
dc.contributor.authorTan, Yong Wah
dc.contributor.authorYam, Wan Keat
dc.contributor.authorSun, Jialei
dc.contributor.authorChu, Justin Jang Hann
dc.date.accessioned2020-08-21T06:05:39Z
dc.date.available2020-08-21T06:05:39Z
dc.date.issued2018-01-01
dc.identifier.citationTan, Yong Wah, Yam, Wan Keat, Sun, Jialei, Chu, Justin Jang Hann (2018-01-01). An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease. ANTIVIRAL RESEARCH 149 : 143-149. ScholarBank@NUS Repository. https://doi.org/10.1016/j.antiviral.2017.11.017
dc.identifier.issn01663542
dc.identifier.issn18729096
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/173279
dc.description.abstract© 2017 Elsevier B.V. A common childhood affliction of viral origin in young children and immunocompromised adults, the Hand, Foot and Mouth Disease (HFMD) has become a significant public health concern in the Asia-Pacific Region. Characterized by the appearance of vesiculopapular rashes on the hands, feet and mouth, the disease is generally mild and self-limiting. In a minority of cases, patients can develop neurological complications that could result in permanent morbidity or even fatality. In the absence of a specific antiviral for treatment, medical care is limited to supportive and symptomatic relief, presenting a need for more research into an effective antiviral to be used in the management of the disease. In this study, we evaluated the efficacy of chloroquine, a FDA-approved lysosomotropic agent, against several serotypes of HFMD-associated enteroviruses, including EV-A71, in reducing infectious virus production. We have also evaluated chloroquine in a murine model of EV-A71 infection to ascertain its antiviral efficacy in vivo. The results suggest that chloroquine could be a broad-acting antiviral effective against HFMD-associated enteroviruses.
dc.language.isoen
dc.publisherELSEVIER SCIENCE BV
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectPharmacology & Pharmacy
dc.subjectVirology
dc.subjectEnterovirus
dc.subjectEV-A71
dc.subjectChloroquine
dc.subjectHFMD
dc.subjectAntiviral
dc.subjectENTEROVIRUS 71
dc.subjectCHINA
dc.subjectEPIDEMIOLOGY
dc.subjectCHILDREN
dc.subjectSINGAPORE
dc.subjectPROTEIN
dc.subjectMALARIA
dc.typeArticle
dc.date.updated2020-06-23T07:54:37Z
dc.contributor.departmentMICROBIOLOGY AND IMMUNOLOGY
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1016/j.antiviral.2017.11.017
dc.description.sourcetitleANTIVIRAL RESEARCH
dc.description.volume149
dc.description.page143-149
dc.published.statePublished
dc.description.redepositcompleted
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
14.pdfAccepted version914.53 kBAdobe PDF

OPEN

Post-printView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.